Objective: Generalized anxiety disorder (GAD) is a persistent mental health condition that results in significant individual and economic burden. The uptake of evidence-based treatment is low, with many individuals with GAD citing cost as one of the key barriers. Brief treatments, which are typically more cost effective than standard length treatments, have the potential to make treatment more accessible to patients with GAD. Despite evidence demonstrating the efficacy of brief treatments for a range of anxiety disorders, there are currently no such studies examining brief Internet videoconferencing-delivered cognitive behavioural therapy (VCBT) interventions for patients with diagnosed GAD. The current study aims to examine the preliminary efficacy and acceptability of brief VCBT for GAD.
Method: The authors adopted an open trial design with 36 participants (77.8% female; M = 36.81 years; SD = 12.25) to examine the preliminary efficacy of a brief five-session VCBT intervention delivered remotely.
Results: Large pre-treatment to post-treatment effects were seen on the primary outcome measure, the Generalized Anxiety Disorder Questionnaire-7 item (GAD-7; d = 1.13; 95% CI: .62-1.61) and treatment effects increased at 3-month follow-up (d = 1.58; 95% CI: 1.04-2.10). Participants rated the intervention as highly acceptable with 92% reporting that they were satisfied with the treatment.
Conclusion: These results provide preliminary support for the viability of brief remotely delivered CBT treatment in managing GAD symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bjc.12516 | DOI Listing |
JAMA Netw Open
January 2025
Department of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
Importance: Mental health issues among young people are increasingly concerning. Conventional psychological interventions face challenges, including limited staffing, time commitment, and low completion rates.
Objective: To evaluate the effect of a low-intensity online intervention on young people in Hong Kong experiencing moderate or greater mental distress.
J Neurol
January 2025
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Background: Married or long-term partnered patients with chronic diseases generally have better outcomes than unmarried patients, likely due to the potential for multifaceted support. However, the impact of marital status on multiple sclerosis (MS) radiographic disease burden is currently unknown.
Objective: To compare total white matter hyperintensity lesion volumes, periventricular lesion volumes, and whole brain and grey matter volumes in married and unmarried people with MS (PwMS).
Rheumatol Int
January 2025
Department of Rheumatology, Immunology and Internal Medicine, University Hospital in Kraków, Kraków, Poland.
Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease (ARD) that results from the dysregulation of multiple innate and adaptive immune pathways. Late-onset SLE (Lo-SLE) is the term used when the disease is first diagnosed after 50-65 years, though the standard age cut-off remains undefined. Defining "late-onset" as lupus with onset after 50 years is more biologically plausible as this roughly corresponds to the age of menopause.
View Article and Find Full Text PDFArch Womens Ment Health
January 2025
Liggins Institute, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.
Purpose: There is limited high-quality evidence about perinatal mental health among women with gestational diabetes. We aimed to assess the risks and longitudinal changes in anxiety, depression, and health-related quality of life comparing women with gestational diabetes and those without among a contemporary cohort of pregnant women.
Methods: Prospective cohort study of participants in the GEMS Trial.
Aliment Pharmacol Ther
January 2025
Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, Massachusetts, USA.
Introduction: Despite the emergence of drugs to treat irritable bowel syndrome (IBS), improving abdominal pain can still be challenging. αδ ligands, such as gabapentin and pregabalin, are sometimes used off-label to tackle this problem. However, evidence for efficacy is limited, and no large-scale studies have been published.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!